Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents

Simple item page
dc.contributor.authorMillot, Frédéric
dc.contributor.authorGuilhot, Joëlle
dc.contributor.authorSuttorp, Meinolf
dc.contributor.authorSedlacek, Petr
dc.contributor.authorDe Bont, Eveline
dc.contributor.authorLi, Chi Kong
dc.contributor.authorKalwak, Krzysztof
dc.contributor.authorLausen, Birgitte
dc.contributor.authorCulic, Srdjana
dc.contributor.authorDworzak, Michael
dc.contributor.authorKaiserova, Emilia
dc.contributor.authorDe Moerloose, Barbara
dc.contributor.authorRoula, Farah
dc.contributor.authorBiondi, Andrea
dc.contributor.authorBaruchel, André
dc.contributor.buuauthorGüneş, Adalet Meral
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Çocuk Hematoloji Anabilim Dalı.tr_TR
dc.contributor.scopusid24072843300tr_TR
dc.date.accessioned2022-12-26T08:28:16Z
dc.date.available2022-12-26T08:28:16Z
dc.date.issued2017-08-17
dc.description.abstractThe EUTOS Long-Term Survival score was tested in 350 children with chronic myeloid leukemia in first chronic phase treated with imatinib and registered in the International Registry for Childhood Chronic Myeloid Leukemia. With a median follow up of 3 years (range, 1 month to 6 years) progression and/or death (whichever came first) occurred in 23 patients. For the entire cohort of patients the 5-year progression-free survival rate was 92% (95% CI: 87%-94%) and the 5-year survival accounting for chronic myeloid leukemia deaths was 97% (95% CI: 94%-99%). Of the 309 patients allocated to low (n=199), intermediate (n=68) and high (n=42) risk groups by the EUTOS Long-Term Survival score, events (progression and/or death) occurred in 6.0%, 8.8% and 26.2%, respectively. Estimates of the 5-year progression-free survival rates according to these three risk groups were 96% (95% CI: 92%-98%), 88% (95% CI: 76%-95%) and 67% (95% CI: 48%-81%), respectively. Differences in progression-free survival according to these risk groups were highly significant (P < 0.0001, overall). The EUTOS Long-Term Survival score showed better differentiation of progression-free survival than the Sokal (<45 years), Euro and EUTOS scores in children and adolescents with chronic myeloid leukemia and should be considered in therapeutic algorithms.en_US
dc.identifier.citationMillot, F. vd. (2017). ''Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents''. Haematologica, 102(10), 1704-1708.en_US
dc.identifier.endpage1708tr_TR
dc.identifier.issn0390-6078
dc.identifier.issue10tr_TR
dc.identifier.pubmed28838993tr_TR
dc.identifier.scopus2-s2.0-85030315435tr_TR
dc.identifier.startpage1704tr_TR
dc.identifier.urihttps://doi.org/10.3324/haematol.2017.170035
dc.identifier.urihttps://haematologica.org/article/view/8218
dc.identifier.urihttp://hdl.handle.net/11452/30082
dc.identifier.volume102tr_TR
dc.identifier.wos000411964200022tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherFerrata Storti Foundationen_US
dc.relation.collaborationYurt dışıtr_TR
dc.relation.journalHaematologicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHematologyen_US
dc.subjectChronic granulocytic-leukemiaen_US
dc.subjectChronic myelogenous leukemiaen_US
dc.subjectPopulation-based registryen_US
dc.subject2904 cml patientsen_US
dc.subjectEuropean leukemianeten_US
dc.subjectMolecular responseen_US
dc.subjectInterferon-alphaen_US
dc.subjectYounger patientsen_US
dc.subjectRandomized cmlen_US
dc.subjectImatiniben_US
dc.subject.emtreeImatiniben_US
dc.subject.emtreeAntineoplastic agenten_US
dc.subject.emtreeAcute graft versus host diseaseen_US
dc.subject.emtreeAdolescenten_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeCancer prognosisen_US
dc.subject.emtreeCancer survivalen_US
dc.subject.emtreeChilden_US
dc.subject.emtreeChronic myeloid leukemiaen_US
dc.subject.emtreeEUTOS scoreen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHemoglobin blood levelen_US
dc.subject.emtreeHigh risk patienten_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeInfanten_US
dc.subject.emtreeInfectionen_US
dc.subject.emtreeIntermediate risk patienten_US
dc.subject.emtreeLeukocyte counten_US
dc.subject.emtreeLong term survival scoreen_US
dc.subject.emtreeLow risk patienten_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeOverall survivalen_US
dc.subject.emtreePreschool childen_US
dc.subject.emtreePrognostic discriminationen_US
dc.subject.emtreeProgression free survivalen_US
dc.subject.emtreeSchool childen_US
dc.subject.emtreeScoring systemen_US
dc.subject.emtreeSpleen sizeen_US
dc.subject.emtreeChronic myeloid leukemiaen_US
dc.subject.emtreeDisease exacerbationen_US
dc.subject.emtreeDisease free survivalen_US
dc.subject.emtreeFollow upen_US
dc.subject.emtreeMortalityen_US
dc.subject.emtreePrognosisen_US
dc.subject.emtreeRegisteren_US
dc.subject.emtreeTreatment outcomeen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAntineoplastic combined chemotherapy protocolsen_US
dc.subject.meshChilden_US
dc.subject.meshChild, preschoolen_US
dc.subject.meshDisease progressionen_US
dc.subject.meshDisease-free survivalen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-up studiesen_US
dc.subject.meshHumansen_US
dc.subject.meshInfanten_US
dc.subject.meshLeukemia, myelogenous, chronic, BCR-ABL positiveen_US
dc.subject.meshMaleen_US
dc.subject.meshPrognosisen_US
dc.subject.meshRegistriesen_US
dc.subject.meshTreatment outcomeen_US
dc.subject.scopusChronic Myeloid Leukemia; Imatinib; Protein Tyrosine Kinase Inhibitoren_US
dc.subject.wosHematologyen_US
dc.titlePrognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescentsen_US
dc.typeArticle
dc.wos.quartileQ1en_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Güneş_vd_2017.pdf
Size:
522.65 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus